Below is a list of the top companies exploring cell therapy treatments for diabetes. [Read more…]
Joint Research Collaboration Aims to Advance Human Clinical Trials for the Treatment of Hypoglycemic Unawareness Patients with Severe Type 1 Diabetes
In the announcement below, the Juvenile Diabetes Research Foundation (JDRF) announced that it will provide Sernova $2.45 million to support a clinical trial at a major transplantation center in the United States.  The purpose of the funding is to advance human clinical trials of Sernova’s novel cell macroencapsulated implantable and scalable Cell Pouch System (CPS) for patients with Severe Type 1 Diabetes and Hypoglycemia Unawareness. [Read more…]
Sernova Announces Agreement with CCRM to Produce Specialized Cells for the Treatment of Diabetes
Today, Sernova announced the exciting news that CCRM will be manufacturing its stem cell technology for diabetes, a disease which affects over 40 million patients. CCRM are experts in the stem cell manufacturing field and will be Sernova’s cell manufacturing arm.
Previously, in September 2015, Sernova announced it had signed a license agreement with the University Health Network (UHN) located in Toronto, Canada, for exclusive worldwide rights to specific technologies developed by two UHN researchers, Dr. Cristina Nostro and Dr. Gordon Keller. This cell manufacturing agreement executes Sernova’s worldwide exclusive license agreement to the Nostro/Keller technology and puts Sernova center stage within the diabetes space, where the company is actively working to secure large pharma partners.
This program is advancing in parallel to Sernova’s hemophilia program with multibillion dollar potential, in which a consortium of academic development partners and full non-dilutive funding ($8.5M Cdn) has been secured through the European Union’s Horizon 2020 grant mechanism. [Read more…]